Mpox: An emerging or re-emerging infection with a potential colossal burden on healthcare globally
- PMID: 40470132
- PMCID: PMC12135148
- DOI: 10.4102/ajlm.v14i1.2644
Mpox: An emerging or re-emerging infection with a potential colossal burden on healthcare globally
Abstract
The World Health Organization identified mpox (formerly known as monkeypox), as a resurgent zoonotic epidemic caused by the mpox virus. It is an emerging and re-emerging pathogen with a range of hosts and geographical distribution worldwide. Peer-reviewed scientific articles from 1958 to 29 August 2024 related to global mpox research were extracted from Web of ScienceTM Core Collection and Google Scholar Databases to gauge the extent of the infection. Mpox is marked by a recent resurgence of infections across continents, with Africa being the hardest-hit region. The mpox re-emergence has shown a new mechanism of transmission, with several causes such as a rise in the number of unvaccinated individuals, behaviour risk factors, waning immunity, genetic evolution, and environmental circumstances. Preventive and control measures of mpox include vaccination and patient isolation, while treatment involves antivirals and antibiotics for secondary bacterial infections. Laboratory diagnosis entailing polymerase chain reaction can be effective for routine purposes, but results of serological tests must be interpreted with caution, because of cross-reacting determinants among orthopoxviruses. The structure and classification of the mpox virus, clinical manifestations, pathophysiology, epidemiology, historical antecedent, therapeutics, vaccines, and laboratory diagnosis of the disease are explicated, showcasing mpox as an emerging or re-emerging infection with a potential colossal burden on healthcare, and its classification as an international public health emergency by the World Health Organization.
What this study adds: This review provides the global situation of mpox as an emerging or re-emerging infection, warranting its designation as an international public health emergency.
Keywords: antivirals; clades; laboratory diagnosis; mpox; vaccines.
© 2025. The Authors.
Conflict of interest statement
The authors declare that they have no financial or personal relationships that may have inappropriately influenced them in writing this article. The author, C.L.O., serves as an editorial board member of this journal. The peer review process for this submission was handled independently, and the author had no involvement in the editorial decision-making process for this manuscript. The author has no other competing interests to declare.
Figures




Similar articles
-
Plausible reasons for the resurgence of Mpox (formerly Monkeypox): an overview.Trop Dis Travel Med Vaccines. 2023 Dec 25;9(1):23. doi: 10.1186/s40794-023-00209-6. Trop Dis Travel Med Vaccines. 2023. PMID: 38143281 Free PMC article. Review.
-
Monkeypox (Mpox) outbreak during COVID-19 pandemic-Past and the future.J Med Virol. 2023 Apr;95(4):e28701. doi: 10.1002/jmv.28701. J Med Virol. 2023. PMID: 36951352 Review.
-
Strengthening Africa's response to Mpox (monkeypox): insights from historical outbreaks and the present global spread.Sci One Health. 2024 Oct 28;3:100085. doi: 10.1016/j.soh.2024.100085. eCollection 2024. Sci One Health. 2024. PMID: 39583938 Free PMC article. Review.
-
Mpox virus (MPXV): comprehensive analysis of pandemic risks, pathophysiology, treatments, and mRNA vaccine development.Naunyn Schmiedebergs Arch Pharmacol. 2025 Jun;398(6):6143-6163. doi: 10.1007/s00210-024-03649-9. Epub 2025 Jan 8. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID: 39777535 Review.
-
Prediction of potential public health risk of the recent multicountry monkeypox outbreak: An update after the end declaration of global public health emergency.Health Sci Rep. 2024 May 29;7(6):e2136. doi: 10.1002/hsr2.2136. eCollection 2024 Jun. Health Sci Rep. 2024. PMID: 38817885 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources